Journal
PEDIATRICS
Volume 120, Issue 5, Pages E1350-E1354Publisher
AMER ACAD PEDIATRICS
DOI: 10.1542/peds.2006-3209
Keywords
neonate; bisphosphonate; hypercalcemia; calcium-sensing receptor; familial hypocalciuric hypercalcemia; neonatal hyperparathyroidism
Categories
Ask authors/readers for more resources
We describe the use of pamidronate to control marked hypercalcemia in an extremely premature infant with neonatal hyperparathyroidism that resulted from an inactivating mutation (R220W) of the calcium-sensing receptor. Despite improvement in bone mineralization and subsequent parathyroidectomy with normalization of the serum calcium level, the combination of chronic lung disease, osteomalacia, and poor thoracic cage growth ultimately proved fatal. Pamidronate therapy seems to be safe in the short-term and effective in helping control hypercalcemia even in the very premature infant, allowing for planned surgical intervention when it becomes feasible.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available